Cyclerion Therapeutics, Inc.
CYCN
$1.53
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 840.86% | 14.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 840.86% | 14.81% | |||
| Cost of Revenue | 521.43% | 55.56% | |||
| Gross Profit | 1,324.32% | -17.78% | |||
| SG&A Expenses | -10.30% | 13.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.57% | 14.76% | |||
| Operating Income | 39.83% | -14.76% | |||
| Income Before Tax | -201.23% | 77.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -201.23% | 77.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -201.23% | 77.33% | |||
| EBIT | 39.83% | -14.76% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -186.82% | 81.13% | |||
| Normalized Basic EPS | 43.38% | 4.41% | |||
| EPS Diluted | -186.82% | 81.13% | |||
| Normalized Diluted EPS | 43.38% | 4.41% | |||
| Average Basic Shares Outstanding | 5.01% | 20.15% | |||
| Average Diluted Shares Outstanding | 5.01% | 20.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||